Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neurotrophic Keratopathy Clear all
Terminated Not applicable Interventional

Corneal Neurotization as a Treatment for Neurotrophic Keratopathy

NCT05809245
View directory record Official record
Conditions
Neurotrophic Corneal Ulcer, Neurotrophic Keratitis, Cranial Nerve V Diseases
Interventions
Corneal neurotization
Procedure
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 9, 2026, 1:32 PM EDT
Recruiting Phase 2 Interventional

A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis

NCT07568730
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
Lacripep, Vehicle Ophthalmic Solution
Drug · Other
Lead sponsor
TearSolutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Carmel, Indiana • Minneapolis, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft

NCT02592330
View directory record Official record
Conditions
Limbal Stem Cell Deficiency
Interventions
Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant
Procedure · Biological
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The THINK Study Incidence of Neurotrophic Keratopathy)

NCT06482164
View directory record Official record
Conditions
Dry Eye
Interventions
Dry Eye Disease
Diagnostic Test
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Laguna Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 9, 2026, 1:32 PM EDT
Recruiting Phase 3 Interventional

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

NCT05555589
View directory record Official record
Conditions
Neurotrophic Keratopathy
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
29
States / cities
Laguna Hills, California • Loma Linda, California • Colorado Springs, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 9, 2026, 1:32 PM EDT
Completed No phase listed Observational

Nerve Growth Factor for the Treatment of Cornea Disease

NCT04552730
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
Cenegermin-Bkbj
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 9, 2026, 1:32 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate

NCT04573647
View directory record Official record
Conditions
Neurotrophic Ulcer, Neurotrophic Keratitis, Neurotrophic Corneal Ulcer, Neurotrophic Keratoconjunctivitis
Interventions
Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]
Drug
Lead sponsor
Sight Medical Doctors PLLC
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 9, 2026, 1:32 PM EDT
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

NCT07519902
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Huntington Beach, California • Laguna Hills, California • Loma Linda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

NCT04957758
View directory record Official record
Conditions
Neurotrophic Keratopathy
Interventions
OC-01 (varenicline) nasal spray 1.2 mg/ml, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Dothan, Alabama • Irvine, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 9, 2026, 1:32 PM EDT
Recruiting No phase listed Observational

Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study

NCT07566975
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine ophthalmic solution 0.1%
Other
Lead sponsor
Neuro-Ophthalmology of Texas
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 9, 2026, 1:32 PM EDT
Recruiting Phase 2 Interventional

Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis

NCT05927428
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
BRM424 Ophthalmic Solution - Dose1, BRM424 Ophthalmic Solution - Dose2
Drug
Lead sponsor
BRIM Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Leland, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Sep 9, 2026, 1:32 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease

NCT06964269
View directory record Official record
Conditions
Autoimmune Diseases, Dry Eye, Neurotrophic Keratitis
Interventions
Acthar Gel 80 UNT/ML Injectable Solution
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis

NCT04485546
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
cenegermin-bkbj
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
San Diego, California • Edgewood, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

NCT04909450
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
CSB-001 Ophthalmic Solution 0.1%, Vehicle Control
Biological
Lead sponsor
Claris Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
45
States / cities
Cave Creek, Arizona • Loma Linda, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 9, 2026, 1:32 PM EDT
Recruiting Phase 4 Interventional

Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency

NCT07502378
View directory record Official record
Conditions
Ocular Surface Disease, Neurotrophic Keratopathy Stage 1
Interventions
Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period., Alternative would be patient exiting the trial and starting on tears or other standard of care.
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 9, 2026, 1:32 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

DOMPE -MT Neurotrophic Keratitis

NCT06947850
View directory record Official record
Conditions
Dry Eye, Neurotrophic Keratitis
Interventions
Cenegermin Ophthalmic Solution [Oxervate]
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 9, 2026, 1:32 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

NCT06919081
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders
Interventions
Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK

NCT02227147
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
rhNGF 20µg/ml, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Loma Linda, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 9, 2026, 1:32 PM EDT
Not listed No phase listed Observational

An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity

NCT05566717
View directory record Official record
Conditions
Diabetic Retinopathy, Neurotrophic Keratitis
Interventions
Not listed
Lead sponsor
Medical Center Ophthalmology Associates
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 9, 2026, 1:32 PM EDT
Terminated Phase 3 Interventional Results available

Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1

NCT02600429
View directory record Official record
Conditions
Neurotrophic Keratopathy
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
Lancaster, California • Colorado Springs, Colorado • Fort Collins, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

NCT04276558
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
Udonitrectag, Vehicle
Drug · Other
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
9
States / cities
Crystal River, Florida • Gainesville, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 9, 2026, 1:32 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

QST for Corneal Nerve Function

NCT05758753
View directory record Official record
Conditions
Corneal Disease, Neuropathy, Dry Eye Disease, Neurotrophic Keratitis
Interventions
Quantitative Sensory Test
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 9, 2026, 1:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Prevalence of Hypoesthesia Related Keratitis in Ocular Graft Vs. Host Disease (GVHD) Patients

NCT04700657
View directory record Official record
Conditions
Ocular GVHD
Interventions
corneal sensation test
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 9, 2026, 1:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis

NCT06999733
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
KB801, Placebo
Biological · Drug
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Irvine, California • Pasadena, California • Carmel, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 9, 2026, 1:32 PM EDT